Montelukast vs Upadacitinib
Montelukast vs Upadacitinib: Overview
This comparison examines the pharmacological differences between Montelukast and Upadacitinib.
Mechanism of Action
Montelukast: Selective leukotriene D4 receptor antagonist.
Upadacitinib: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.
Pharmacokinetics
Half-life: Montelukast β 2.7-5.5 hours; Upadacitinib β 9-14 hours.
Chemical Properties
Molecular Formula: Montelukast β C35H36ClNO3S; Upadacitinib β C17H19F3N6O.
Molecular Weight: Montelukast β 586.1800 g/mol; Upadacitinib β 380.3700 g/mol.
Type: Montelukast β Small molecule; Upadacitinib β Small molecule.